Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open-label, parallel-design, multicenter, Phase III study to compare the safety and efficacy of a fixed dose combination of SULBACTOMAX Vs CEFTRIAXONE in the treatment of hospitalized adult patients with Community-Acquired Pneumonia

Trial Profile

A randomized, open-label, parallel-design, multicenter, Phase III study to compare the safety and efficacy of a fixed dose combination of SULBACTOMAX Vs CEFTRIAXONE in the treatment of hospitalized adult patients with Community-Acquired Pneumonia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftriaxone/sulbactam (Primary) ; Ceftriaxone
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms LRTI2011KR
  • Sponsors Korea Pharma
  • Most Recent Events

    • 11 Dec 2013 Planned number of patients changed from 124 to 248 as reported by Korean Clinical Trials Register record.
    • 10 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top